tbuckley/cabot-search huggingface dataset:
Abstract 595: Tumor suppressor <i>SCUBE2</i> inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition
Authors: Yuh-Charn Lin, Yi-Ching Lee, Ling-Hui Li, Chien-Jui Cheng, Ruey-Bing Yang
Journal: Cancer Research (2014)

Abstract Signal peptide-CUB-EGF domain-containing protein 2 (SCUBE2) belongs to a secreted and membrane-associated multi-domain SCUBE protein family. We previously demonstrated that SCUBE2 is a novel breast-tumor suppressor and could be a useful prognostic marker. However, the role of SCUBE2 in breast-cancer cell migration and invasion and how it is regulated during the epithelial-mesenchymal transition (EMT) remain undefined. In this study, we showed that ectopic SCUBE2 overexpression could enhance the formation of E-cadherin-containing adherens junctions by β-catenin-SOX-mediated induction of forkhead box A1 (a positive regulator of E-cadherin) and upregulation of E-cadherin, which in turn led to epithelial transition and inhibited migration and invasion of aggressive MDA-MB-231 breast-carcinoma cells. SCUBE2 expression was repressed together with that of E-cadherin in TGF-β-induced EMT; direct expression of SCUBE2 alone was sufficient to inhibit the TGF-β-induced EMT. Furthermore, quantitative DNA methylation, methylation-specific PCR, and chromatin immunoprecipitation analyses revealed that SCUBE2 expression was inactivated by DNA hypermethylation at the CpG islands by recruiting and binding DNA methyltransferase 1 during TGF-β-induced EMT. Together, our results suggest that SCUBE2 plays a key role in suppressing breast-carcinoma cell mobility and invasiveness by increasing the formation of the epithelial E-cadherin-containing adherens junctions to promote epithelial differentiation and drive the reversal of EMT. Citation Format: Yuh-Charn Lin, Yi-Ching Lee, Ling-Hui Li, Chien-Jui Cheng, Ruey-Bing Yang. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 595. doi:10.1158/1538-7445.AM2014-595
Abuse Deterrent Formulations of Prescription Opioids—Reply
Authors: Theodore J. Cicero, Matthew S. Ellis
Journal: JAMA Psychiatry (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Status of complete proteome analysis by mass spectrometry:  SILAC labeled yeast as a model system.
Authors: Lyris MF de Godoy, Jesper V Olsen, Gustavo A de Souza, Guoqing Li, Peter Mortensen, Matthias Mann
Journal: Genome biology (2006)

Abstract Background Mass spectrometry has become a powerful tool for the analysis of large numbers of proteins in complex samples, enabling much of proteomics. Due to various analytical challenges, so far no proteome has been sequenced completely. O'Shea, Weissman and co-workers have recently determined the copy number of yeast proteins, making this proteome an excellent model system to study factors affecting coverage. Results To probe the yeast proteome in depth and determine factors currently preventing complete analysis, we grew yeast cells, extracted proteins and separated them by one-dimensional gel electrophoresis. Peptides resulting from trypsin digestion were analyzed by liquid chromatography mass spectrometry on a linear ion trap-Fourier transform mass spectrometer with very high mass accuracy and sequencing speed. We achieved unambiguous identification of more than 2,000 proteins, including very low abundant ones. Effective dynamic range was limited to about 1,000 and effective sensitivity to about 500 femtomoles, far from the subfemtomole sensitivity possible with single proteins. We used SILAC (stable isotope labeling by amino acids in cell culture) to generate one-to-one pairs of true peptide signals and investigated if sensitivity, sequencing speed or dynamic range were limiting the analysis. Conclusion Advanced mass spectrometry methods can unambiguously identify more than 2,000 proteins in a single proteome. Complex mixture analysis is not limited by sensitivity but by a combination of dynamic range (high abundance peptides preventing sequencing of low abundance ones) and by effective sequencing speed. Substantially increased coverage of the yeast proteome appears feasible with further development in software and instrumentation.
Abstract 14740: Cardiac Magnetic Resonance Imaging Or Endomyocardial Biopsy For The Diagnosis Of Myocarditis And Viral Heart Disease
Authors: Bernhard Maisch, Peter Alter, Marga Rominger, Roland Moll, Ulrik Baandrup, Sabine Pankuweit
Journal: Circulation (2011)

Purpose: Cardiac MRI(CMRI) has been proposed as non-invasive diagnostic standard of myocarditis. However, it has not been systematically validated against the undisputed histological standard of in...
Impaired Ca2+-Induced Tyrosine Phosphorylation and Defective Lipid Scrambling in Erythrocytes From a Patient With Scott Syndrome: A Study Using an Inhibitor for Scramblase That Mimics the Defect in Scott Syndrome
Authors: David W.C. Dekkers, Paul Comfurius, Wim M.J. Vuist, Jeffrey T. Billheimer, Ira Dicker, Harvey J. Weiss, Robert F. A. Zwaal, Edouard M. Bevers
Journal: Blood (1998)
Abstract 13125: Sedentary Behaviour and Physical Activity Among Older Patients Following Percutaneous Coronary Intervention Presented with Stable Angina versus Acute Coronary Syndrome
Authors: Sarah J Denton, Vincent T van Hees, Bilal Bawamia, Murugapathy Veerasamy, Louise Quinn, Joseph R Dunford, Michael I Trenell, Djordje G Jakovljevic, Vijay Kunadian
Journal: Circulation (2014)

Introduction: A wide variety of exercise regimes produce significant reductions in coronary artery disease (CAD) risk and modulate the pathogenesis of CAD. Given the ongoing burden of cardiovascular disease and an aging population, physical activity (PA) in patients with CAD needs to be emphasized in addition to the use of advanced therapeutic and pharmacological interventions in their management. It is not known whether PA levels differ among older patients following percutaneous coronary intervention (PCI) for stable angina (SA) vs. acute coronary syndrome (ACS) consisting of ST-segment elevation myocardial infarction (STEMI) and non STEMI (NSTEMI). Hypothesis: To determine differences in the distribution of time spent in acceleration categories reflecting sedentary behaviour and PA in older patients (≥75 years) following PCI. Methods: We evaluated sedentary behaviour and PA amongst patients following PCI for SA (n=20), STEMI (n=20) and NSTEMI (n=18) upon discharge from a tertiary centre over a 7-day period using wrist-worn triaxial accelerometers (GENEActiv, Activinsights Ltd, United Kingdom). Results: Mean ± Standard deviation age was 79±4 years (31% female). STEMI and NSTEMI patients spent more time in the lowest acceleration category (0-40mg) than SA patients (1298±59 and 1305±66 vs. 1240±92 minutes/day, p&lt;0.05). STEMI and NSTEMI patients spent less time than SA patients in the 40-80mg acceleration category (95±35 and 94±41 vs. 132±50 minutes/day, p&lt;0.05). These trends continued for acceleration categories 80-120mg (p&lt;0.05) and 120-160mg (p&lt;0.05) but only between SA and NSTEMI patients. SA patients spent more time than NSTEMI patients in the 1 (15±18 vs. 6±9 minutes/day, p&lt;0.05) and 5 (6±10 and 1±3 minutes/day, p&lt;0.05) minute moderate-vigorous intensity PA bouts (≥100mg category). For the higher acceleration categories (≥160 mg), no differences between the groups were observed. Conclusions: Patients presenting with ACS and undergoing PCI spent more time in the low acceleration category reflecting sedentary behaviour and sleep compared with SA patients. Following PCI for ACS, strategies may need to be put in place to ensure that ACS patients achieve the mid category acceleration.
Effects of exercise training on depression in patients with heart failure: a systematic review and meta‐analysis of randomized controlled trials
Authors: Rong‐Hui Tu, Zhi‐Yu Zeng, Guo‐Qiang Zhong, Wei‐Feng Wu, Yun‐Juan Lu, Zhan‐Dong Bo, Yan He, Wei‐Qiang Huang, Li‐Mei Yao
Journal: European Journal of Heart Failure (2014)
Abstract 4309: Whole slide image analysis quantification in a mouse lung metastasis model
Authors: George E. Sandusky, Ronne Surface, Eva Tonsing-Carter, jayne Silver, Tony Sinn, Karen Pollok
Journal: Cancer Research (2014)

Abstract Digital whole slide imaging is the technique of digitizing a microscope slide at the highest resolution to produce a “digital virtual microscope slide”. This digital image can be viewed in three or four fields, from low to high power fields, which can be commonly used to evaluate the tissue. Many of these systems have a whole slide software image analysis system. The goal of this study was to determine if the Aperio positive pixel algorithm (image analysis) could effectively quantitate metastatic mouse lung tumors in a lung section using a H&amp;E stain. Lung sections from a mouse lung metastasis model with 8 mice in each group were evaluated: control, 50mg/kg, and 75mg/kg carboplatin. H&amp;E and Ki67 immunostain slides were scanned using the Aperio whole slide scanning system (Scanscope CS). A single field of view from each slide representing a whole lung lobe with multiple lung metastases was selected for image analysis. The standard positive pixel algorithm was altered to read the H&amp;E slides. Various histology slides were used to validate the altered algorithm. The immunostain (Ki67) was generated using the standard positive pixel algorithm analysis. The Aperio automated positive pixel count for a Ki67 immunostain was consistent with the H&amp;E image analysis. The values went down with a dose dependent treatment (control vs. 50mg/kg, and 75mg/kg Carboplatin) and were (H&amp;E) 37%, 28%, 22%, and (Ki67) 9%, 5%, 3%, respectively. The analysis had decreasing values for both the H&amp;E and Ki67 analysis on a dose dependent drug treatment. The metastases decreased in both treatment groups compared to controls with both the H&amp;E and Ki67 analyses. The Aperio Image Analysis positive pixel algorithm allows large areas of the lung tissue section to be examined and NOT just a single 25x or 40x field like many common image analyses. Citation Format: George E. Sandusky, Ronne Surface, Eva Tonsing-Carter, jayne Silver, Tony Sinn, Karen Pollok. Whole slide image analysis quantification in a mouse lung metastasis model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4309. doi:10.1158/1538-7445.AM2014-4309
Abstract 4124: Ovarian cancer survival by tumor subtype
Authors: Elizabeth M. Poole, Daniel W. Cramer, Allison F. Vitonis, Kathryn L. Terry
Journal: Cancer Research (2014)

Abstract Introduction: Epithelial ovarian cancer is heterogeneous, with subgroups defined by cell of origin (ovary vs. fallopian tube), histology, and carcinogenic pathway (the etiologic pathway through which tumors arise: type I tumors develop on the ovarian surface and are low grade serous or mucinous histology; type II tumors develop through endometriotic implantation and are clear cell or endometrioid histology; type III tumors originate in the fallopian tube and are high grade serous histology). Although differences in associations have been observed with risk of incident ovarian cancer, few studies have examined differences in survival by subtype. In the New England Case-Control Study of ovarian cancer (NECC), we examined differences in survival by tumor dominance (a surrogate for cell of origin), histology, and carcinogenic pathway. Methods: Among 2076 women with epithelial ovarian cancer (1991-2008), 892 deaths were observed. Cox proportional hazards regression was used to calculate hazards ratios (HRs) and 95% confidence intervals (95% CI) for the association of ovarian cancer subtype with overall survival, adjusting for age at diagnosis, study phase, year of diagnosis (as a proxy for treatment), BMI, and smoking status. Results: Serous invasive tumors were more likely to be non-dominant (likely fallopian origin) and type III. Compared to serous invasive tumors, all other tumor histologies had statistically significantly improved survival. Similarly, dominant tumors (i.e., likely ovarian origin) had greater survival than non-dominant tumors (HR: 0.38; 95% CI: 0.31-0.47). Type I (mucinous and low grade serous) and type II (endometrioid and clear cell) tumors had better survival than type III (high grade serous) tumors (HR: 0.21; 95%CI: 0.16-0.28 and HR: 0.23; 95% CI: 0.18-0.29, respectively). Conclusion: Regardless of how subtype was defined, high grade, invasive serous tumors had worse survival compared to other tumor subtypes. This underscores the need for prevention and treatment targeted at these aggressive tumors. Table.Associations between tumor subtype and overall survivalSubtypeDeaths/CasesMedian Survival (years)HR (95% CI)HistologySerous invasive654/9683.21.00 (ref.)Serous borderline25/25010.10.35 (0.18-0.67)Mucinous36/2427.10.38 (0.25-0.58)Endometrioid68/3314.70.28 (0.21-0.37)Clear cell29/1163.40.30 (0.21-0.44)DominanceNon-dominant268/3853.31.00 (ref.)Dominant162/6034.00.38 (0.31-0.47)PathwayType III596/8563.21.00 (ref.)Type II97/4474.00.23 (0.18-0.29)Type I60/2915.70.21 (0.16-0.28) Citation Format: Elizabeth M. Poole, Daniel W. Cramer, Allison F. Vitonis, Kathryn L. Terry. Ovarian cancer survival by tumor subtype. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4124. doi:10.1158/1538-7445.AM2014-4124
A workshop on the marrow microenvironment and hematological malignancy.
Authors: Yong Sung Choi, Kenneth Anderson, R Allan Mufson
Journal: Cancer Research (2003)

The Division of Cancer Biology of the National Cancer Institute hosted a workshop on hematological malignancies and the marrow microenvironment in Rockville, Maryland in the fall of 2002. There were 22 invited participants from the United States, Canada, and Europe, and the workshop was organized into disease-specific sessions. The sessions were designed to explore the basic science and therapeutic applications related to the stromal and nonstromal components of the marrow in malignant hematological diseases.
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients
Authors: Jeremie Guedj, Jing Yu, Micha Levi, Bin Li, Steven Kern, Nikolai V. Naoumov, Alan S. Perelson
Journal: Hepatology (2013)

Alisporivir (ALV) is a cyclophilin inhibitor with pan-genotypic activity against hepatitis C virus (HCV). Here, we characterize the viral kinetics observed in 249 patients infected with HCV genotypes 2 or 3 and treated for 6 weeks with different doses of ALV with or without ribavirin (RBV). We use this model to predict the effects of treatment duration and different doses of ALV plus RBV on sustained virologic response (SVR). Continuous viral decline was observed in 214 (86%) patients that could be well described by the model. All doses led to a high level of antiviral effectiveness equal to 0.98, 0.96, and 0.90 in patients treated with 1,000, 800, and 600 mg of ALV once-daily, respectively. Patients that received RBV had a significantly faster rate of viral decline, which was attributed to an enhanced loss rate of infected cells, δ (mean δ = 0.35 d−1 vs. 0.21 d−1 in patients ± RBV, respectively; P = 0.0001). The remaining 35 patients (14%) had a suboptimal response with flat or increasing levels of HCV RNA after 1 week of treatment, which was associated with ALV monotherapy, high body weight, and low RBV levels in patients that received ALV plus RBV. Assuming full compliance and the same proportion of suboptimal responders, the model predicted 71% and 79% SVR after ALV 400 mg with RBV 400 mg twice-daily for 24 and 36 weeks, respectively. The model predicted that response-guided treatment could allow a reduction in mean treatment duration to 25.3 weeks and attain a 78.6% SVR rate. Conclusion: ALV plus RBV may represent an effective IFN-free treatment that is predicted to achieve high SVR rates in patients with HCV genotype 2 or 3 infection. (Hepatology 2014;59:1706–1714)
The Crystal Structure of a TL/CD8αα Complex at 2.1 Å Resolution
Authors: Yiwei Liu, Yi Xiong, Olga V. Naidenko, Jin-huan Liu, Rongguang Zhang, Andrzej Joachimiak, Mitchell Kronenberg, Hilde Cheroutre, Ellis L. Reinherz, Jia-huai Wang
Journal: Immunity (2003)
Impact of Long Working Hours Explored
Authors: Lynne Lamberg
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P4-12-12: Next generation sequencing-based analysis of BRCA1 and BRCA2 genes: Applicability for fast diagnostics of large samples
Authors: Sun-Young Kong, Eunhae Cho, Junnam Lee, Myong Cheol Lim, Jahyun Jang, Boyoung Park, Kyong-Ah Yoon, Young-Ho Kim, Eun Sook Lee
Journal: Cancer Research (2015)

Abstract Purpose BRCA1&amp;2 gene mutation test for hereditary breast ovarian syndrome (HBOC) has been conducted mostly by Sanger sequencing. Currently, the next generation sequencing (NGS) is rapidly incorporated to the fields of cancer research and clinical diagnostics. Here we evaluated NGS-based results of BRCA gene analysis and compared with the results of Sanger sequencing for future diagnostic applications. Methods The patients (n=100) who have genetic counseling and decided to perform BRCA test were included. All coding regions of BRCA1 and BRCA2 analyzed by both of Sanger sequencing and NGS using Access Array BRCA1, BRCA2 and TP53 kit (Fluidigm, USA). Access array kit was designed to multiplex 48 samples simultaneously for 184 amplicons and the average sequencing depth per base was 6,500X using MiSeq sequencer (Illumina, USA). We developed analysis pipelines to avoid false negative results and detect all pathogenic mutations. The reads were aligned to a reference genome (NCBI human genome assembly build 37) using the BWA-MEM, then all candidate variants called with minimum filtering parameter. Results Total of 765 variants were detected by NGS and among them 616 variants (frameshift:22, nonsense:8, splicing:3, missense:290, and synonymous variants:293) were identical with the results from Sanger sequencing. When we evaluated the results of Sanger sequencing as standard methods, the mean allele frequency showed difference as 41.7% and 12.0% for true positive heterozygous variants (616) and false positive variants (149), respectively. Conclusions There was no false negative of pathogenic mutations from NGS. The BRCA mutation detection using NGS represented potential applicability in clinical diagnosis. Citation Format: Sun-Young Kong, Eunhae Cho, Junnam Lee, Myong Cheol Lim, Jahyun Jang, Boyoung Park, Kyong-Ah Yoon, Young-Ho Kim, Eun Sook Lee. Next generation sequencing-based analysis of BRCA1 and BRCA2 genes: Applicability for fast diagnostics of large samples [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-12-12.
Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
Authors: Addolorata Maria Luce Coluccia, Teresa Cirulli, Paola Neri, Domenica Mangieri, Maria Cristina Colanardi, Antonio Gnoni, Nicola Di Renzo, Franco Dammacco, Pierfrancesco Tassone, Domenico Ribatti, Carlo Gambacorti-Passerini, Angelo Vacca
Journal: Blood (2008)
Journal: Men's Health Journal
Authors: T. O'Dowd
Journal: BMJ (2001)

Quarterly journal of the Men's Health Forum Personal subscription: UK £30; overseas £45. Institutional subscription: UK £75, overseas £90 For further details, telephone 01279 714510 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> Considering the power and influence wielded by men in both medicine and politics it is odd that, unlike women, they have ignored the clear adverse health profiles of their own gender. In the first issue of the Men's Health Journal , public health minister Yvette Cooper considers the fact that, on average, men die five years younger than women to be “one of the starkest health inequalities we face.” … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif